[1] WU T Z,LI J,SHAO L,et al.Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver falure[J].Gut,2018,67(12):2181-2191. [2] 梁群英,梁运霞,邱晓娣,等.肝穿刺行活体组织检查的临床病理分析[J].实验与检验医学,2019,37(4):745-750. [3] 中华医学会感染病学分会,中华医学会肝病学分会.慢性乙型肝炎防治指南(2019年版)[J].中华肝脏病杂志,2019,27(12):938-961. [4] TIO M,RAI R,EZEOKE O M,et al.Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant,HIV or hepatitis B/C infection[J].Eur J Cancer,2018,104:137-144. [5] BALKAN A,YILMAZ N,BALKAN Y,et al.Relationship between liver injury and serum cytokeratin 18 levels in asymptomatic hepatitis B virus carriers and in patients with chronic hepatitis B infection[J].Arab J Gastroenterol,2017,18(2):98-103. [6] BARNES E.Unravelling the fate of functional PD1+T cells in chronic viral hepatitis[J].J Clin Invest,2018,128(2):573-576. [7] AKSOY E K,SIMSEK G G,TORGUTALP M,et al.Expression of M30 and M65 in celiac disease.Analytical cross-sectional study[J].Sao Paulo Med J,2018,136(6):525-532. [8] CHANG Y H,LIN H C,HWU D W,et al.Elevated serum cytokeratin-18 concentration in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease[J].Annals of clinical biochemistry,2019,56(1):141-147. [9] 汤珊,梅婷婷,柳雅立,等.乙型肝炎相关显著肝纤维化无创预测指标及模型的研究[J].北京医学,2019,41(6):509-511. [10] 中华医学会传染病与寄生虫病学分会,肝病学分会.病毒性肝炎防治方案[J].中华肝脏病杂志,2000,8(6):324-329. [11] 喻雪琴,张诗琬,陈芳,等.HBV相关性肝病患者外周血PBMCs表面Tim-3、PD-1表达水平检测及意义[J].中国现代医学杂志,2019,29(19):43-47. [12] 秦维,杨昭,祝素平.共刺激分子在慢性HBV感染患者中的表达及对低复制与再活动阶段表达意义的研究[J].胃肠病学和肝病学杂志,2018,6(1):689-692. [13] 郭世民,魏巍,张自然,等.血清M30及M65水平用于HBV相关慢加急性肝衰竭患者预后的临床价值[J].临床肝胆病杂志,2018,23(7):607-611.
